Objectives

·  Describe real-world and clinical trial outcomes of long-acting ART in people with HIV and viremia, including rates of viral suppression despite adherence challenges.

·  Identify key implementation strategies that enable successful scale-up of long-acting ART in high-burden settings.

·  Explain how expanding long-acting ART for viremic populations can improve viral suppression and contribute to Ending the HIV Epidemic goals.